Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury

Frontiers in Pharmacology

Volumn 5, Issue NOV, 2014, Pages

  Woodhead, Jeffrey L ^a   Yan, Kyunghee ^a   Siler, Scott Q ^a   Watkins, Paul B ^a   Brouwer, Kim L R ^b   Barton, Hugh A ^c   Howell, Brett A ^a  

^a HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

^b University of North Carolina   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; BILE SALT EXPORT PUMP; CP 724 714; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; TELMISARTAN; UNCLASSIFIED DRUG;

ARTICLE; BIOACCUMULATION; COMPETITIVE INHIBITION; COMPUTER MODEL; COMPUTER SIMULATION; CONCENTRATION (PARAMETERS); DILISYM MODEL; DRUG METABOLISM; DRUG SCREENING; HUMAN VERSUS ANIMAL COMPARISON; INTERMETHOD COMPARISON; LIVER INJURY; LIVER TOXICITY; MITOCHONDRIAL ENERGY TRANSFER; PREDICTION; PROCESS DEVELOPMENT; VALIDATION PROCESS;

EID: 84949116921     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00240     Document Type: Article

References (39)

1. Aleo, M., Luo, Y., Swiss, R., and Bonin, P. (2014). Human drug-induced liver injury severity is highly associated to dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology 60, 1015-1022. doi: 10.1002/hep.27206
2. Ansede, J. H., Smith, W. R., Perry, C. H., St Claire, R. L. 3rd., and Brouwer, K. R. (2010). An in vitro assay to assess transporter-based cholestatic hepatotoxicity using sandwich-cultured rat hepatocytes. Drug Metab. Dispos. Biol. Fate Chem . 38, 276-280. doi: 10.1124/dmd.109.028407
3. Chatterjee, S., Bijsmans, I. T. G. W., van Mil, S. W. C., Augustijns, P., and Annaert, P. (2013). Toxicity and intracellular accumulation of bile acids in sandwich-cultured rat hepatocytes: role of glycine conjugates. Toxicol. Vitro Int. J. Publ. Assoc . 28, 218-230. doi: 10.1016/j.tiv.2013.10.020
4. Dawson, S. E., Stahl, S., Paul, N., Barber, J., and Kenna, J. G. G. (2011). In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug induced liver injury in man. Drug Metab. Dispos. Biol. Fate Chem . 40, 130-138. doi: 10.1124/dmd.111.040758
5. Dingemanse, J., and van Giersbergen, P. L. M. (2004). Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin. Pharmacokinet . 43, 1089-1115. doi: 10.2165/00003088-200443150-00003
6. Eriksson, C., Gustavsson, A., Kronvall, T., and Tysk, C. (2011). Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature. J. Gastrointest. Liver Dis . 20, 77-80.
7. Fattinger, K., Funk, C., Pantze, M., Weber, C., Reichen, J., Stieger, B., et al. (2001). The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther . 69, 223-231. doi: 10.1067/mcp.2001.114667
8. Feng, B., Xu, J. J., Bi, Y.-A., Mireles, R., Davidson, R., Duignan, D. B., et al. (2009). Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714. Toxicol. Sci . 108, 492-500. doi: 10.1093/toxsci/kfp033
9. Fouassier, L., Kinnman, N., Lefèvre, G., Lasnier, E., Rey, C., Poupon, R., et al. (2002). Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan. J. Hepatol . 37, 184-191. doi: 10.1016/S0168-8278(02)00107-1
10. Funk, C., Pantze, M., Jehle, L., Ponelle, C., Scheuermann, G., Lazendic, M., et al. (2001). Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology 167, 83-98. doi: 10.1016/S0300-483X(01)00460-7
11. García-Cañaveras, J. C., Donato, M. T., Castell, J. V., and Lahoz, A. (2012). Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS-validated method. J. Lipid Res . 53, 2231-2241. doi: 10.1194/jlr.D028803
12. Guo, F., Letrent, S. P., Munster, P. N., Britten, C. D., Gelmon, K., Tolcher, A. W., et al. (2008). Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety. Cancer Chemother. Pharmacol . 62, 97-109. doi: 10.1007/s00280-007-0579-4
13. Hofmann, A. F. (2004). Detoxification of lithocholic acid, a toxic bile acid: relevance to drug hepatotoxicity. Drug Metab. Rev . 36, 703-722. doi: 10.1081/DMR-200033475
14. Hofmann, A. F. (2009). The enterohepatic circulation of bile acids in mammals: form and functions. Front. Biosci . 14, 2584-2598. doi: 10.2741/3399
15. Howell, B. A., Siler, S. Q., Shoda, L. K. M., Yang, Y., Woodhead, J. L., and Watkins, P. B. (2014). A mechanistic model of drug-induced liver injury AIDS the interpretation of elevated liver transaminase levels in a phase I clinical trial. CPT Pharmacomet. Syst. Pharmacol . 3, e98. doi: 10.1038/psp.2013.74
16. Howell, B. A., Yang, Y., Kumar, R., Woodhead, J. L., Harrill, A. H., Clewell, H. J. 3rd, et al. (2012). In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI. J. Pharmacokinet. Pharmacodyn . 39, 527-541. doi: 10.1007/s10928-012-9266-0
17. Kis, E., Ioja, E., Nagy, T., Szente, L., Herédi-Szabó, K., and Krajcsi, P. (2009). Effect of membrane cholesterol on BSEP/Bsep activity: species specificity studies for substrates and inhibitors. Drug Metab. Dispos. Biol. Fate Chem . 37, 1878-1886. doi: 10.1124/dmd.108.024778
18. Kostrubsky, S. E., Strom, S. C., Kalgutkar, A. S., Kulkarni, S., Atherton, J., Mireles, R., et al. (2006). Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol. Sci . 90, 451-459. doi: 10.1093/toxsci/kfj095
19. Lauer, B., Tuschl, G., Kling, M., and Mueller, S. O. (2009). Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem. Biol. Interact . 179, 17-24. doi: 10.1016/j.cbi.2008.10.031
20. Leslie, E. M., Watkins, P. B., Kim, R. B., and Brouwer, K. L. R. (2007). Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity. J. Pharmacol. Exp. Ther . 321, 1170-1178. doi: 10.1124/jpet.106.119073
21. Mano, Y., Usui, T., and Kamimura, H. (2007). Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2. Biopharm. Drug Ldots 18, 13-18. doi: 10.1002/bdd.527
22. Markova, S. M., De Marco, T., Bendjilali, N., Kobashigawa, E. A., Mefford, J., Sodhi, J., et al. (2013). Association of CYP2C9*2 with bosentan-induced liver injury. Clin. Pharmacol. Ther . 94, 678-686. doi: 10.1038/clpt.2013.143
23. Masubuchi, Y. (2006). Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review. Drug Metab. Pharmacokinet . 21, 347-356. doi: 10.2133/dmpk.21.347
24. Meier, Y., Pauli-Magnus, C., Zanger, U. M., Klein, K., Schaeffeler, E., Nussler, A. K., et al. (2006). Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatol . 44, 62-74. doi: 10.1002/hep.21214
25. Ménochet, K., Kenworthy, K. E., Houston, J. B., and Galetin, A. (2012). Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model. J. Pharmacol. Exp. Ther . 341, 2-15. doi: 10.1124/jpet.111.187112
26. Meredith, P. A. (1999). Optimal dosing characteristics of the angiotensin II receptor antagonist telmisartan. Am. J. Cardiol . 84, 7K-12K. doi: 10.1016/S0002-9149(99)00400-2
27. Morgan, R. E., van Staden, C. J., Chen, Y., Kalyanaraman, N., Kalanzi, J., Dunn, R. T., et al. (2013). A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol. Sci . 136, 216-241. doi: 10.1093/toxsci/kft176
28. Munster, P. N., Britten, C. D., Mita, M., Gelmon, K., Minton, S. E., Moulder, S., et al. (2007). First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors. Clin. Cancer Res . 13, 1238-1245. doi: 10.1158/1078-0432.CCR-06-1539
29. Schulz, S., Schmitt, S., Wimmer, R., Aichler, M., Eisenhofer, S., Lichtmannegger, J., et al. (2013). Progressive stages of mitochondrial destruction caused by cell toxic bile salts. Biochim. Biophys. Acta 1828, 2121-2133. doi: 10.1016/j.bbamem.2013.05.007
30. ®), a mechanistic mathematical model of drug-induced liver injury. Biopharm. Drug Dispos . 35, 33-49. doi: 10.1002/bdd.1878
31. Smith, M. T. (2003). Mechanisms of troglitazone hepatotoxicity. Chem. Res. Toxicol . 16, 679-687. doi: 10.1021/tx034033e
32. Stangier, J., Su, C. A., and Roth, W. (2000). Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J. Int. Med. Res . 28, 149-167. doi: 10.1177/147323000002800401
33. Ubeaud, G., Schmitt, C., and Jaeck, D. (1995). Bosentan, a new endothelin receptor antagonist: prediction of the systemic plasma clearance in man from combined in vivo and in vitro data. Xenobiotica 25, 1381-1390. doi: 10.3109/00498259509061925
34. Weber, C., Schmitt, R., Birnboeck, H., Hopfgartner, G., Marle, S. P. V., and Jones, C. (1996). Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin. Pharmacol. Ther . 60, 124-137. doi: 10.1016/S0009-9236(96)90127-7
35. Woodhead, J. L., Howell, B. A., Yang, Y., Harrill, A. H., Clewell, H. J. 3rd., Andersen, M. E., et al. (2012). An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. J. Pharmacol. Exp. Ther . 342, 529-540. doi: 10.1124/jpet.112.192930
36. Woodhead, J. L., Yang, K., Brouwer, K. L. R., Siler, S. Q., Stahl, S. H., Ambroso, J. L., et al. (2014). Mechanistic modeling reveals the critical knowledge gaps in bile acid-mediated DILI. CPT Pharmacomet. Syst. Pharmacol . 3, e123. doi: 10.1038/psp.2014.21
37. Yang, K., Woodhead, J. L., Watkins, P. B., Howell, B. A., and Brouwer, K. L. (2014). Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity. Clin. Pharmacol. Ther . 96, 589-598. doi: 10.1038/clpt.2014.158
38. Yang, K., Woodhead, J. L., St. Claire, R., Watkins, P. B., Siler, S. Q., Howell, B. A., et al. (2013). Quantitative relationship between intracellular lithocholic acid and toxicity in rat sandwich-cultured hepatocytes: incorporation into a mechanistic model of drug-induced liver injury. Toxicologist 132:226.
39. Yoshikado, T., Takada, T., Yamamoto, T., Yamaji, H., Ito, K., Santa, T., et al. (2011). Itraconazole-induced cholestasis: involvement of the inhibition of bile canalicular phospholipid translocator MDR3/ABCB4. Mol. Pharmacol . 79, 241-250. doi: 10.1124/mol.110.067256